Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 5/20 | 0.60 |
| ▸ | HMGCR | P04035 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8170743 | 0.90 | FDPS (0.61) | FDPSHMGCRPKMKMT2ALMNA | |
| SCHEMBL8170213 | 0.85 | FDPS (0.66) | FDPSPKMKMT2ATDP1CHRNB2 | |
| SCHEMBL27517905 | 0.82 | FDPS (0.50) | FDPSPKMKMT2ALMNAMAPK1 | |
| SCHEMBL8167994 | 0.82 | FDPS (0.60) | FDPSHMGCRPOLB | |
| SCHEMBL8170507 | 0.81 | HMGCR (0.55) | FDPSHMGCRLMNAALDH1A1POLB | |
| Lithium Ion SCHEMBL8712331 | 0.80 | FDPS (0.45) | FDPSPKMKMT2ALMNAMAPK1 | |
| SCHEMBL8712326 | 0.80 | FDPS (0.48) | FDPSPKMKMT2ALMNAMAPK1 | |
| SCHEMBL18307753 | 0.79 | FDPS (0.43) | FDPSPKMKMT2ATDP1CHRNB2 | |
| SCHEMBL5367565 | 0.78 | KMT2A (0.50) | FDPSPKMKMT2ATDP1L3MBTL1 | |
| SCHEMBL578225 | 0.76 | FDPS (0.45) | FDPSPKMKMT2ATDP1CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1482953-A4 | ALPHA-SUBSTITUTED HETEROARYLALKYL PHOSPHONATE DERIVATTIVES | ILEX PRODUCTS INC (US) | 2006-12-13 | — | — | EP | disclosed |
| US-6939880-B2 | Compounds with growth hormone releasing properties | NOVO NORDISK A/S (DK) | 2005-09-06 | — | — | US | disclosed |
| US-20050124581-A1 | Alpha-substituted heteroarylalkyl phosphonate derivatives | PHAN HIEU T (CH) | 2005-06-09 | — | — | US | disclosed |
| EP-1482953-A1 | ALPHA-SUBSTITUTED HETEROARYLALKYL PHOSPHONATE DERIVATTIVES | Ilex Products, Inc. (US) | 2004-12-08 | — | — | EP | disclosed |
| WO-2003068240-A1 | ALPHA-SUBSTITUTED HETEROARYLALKYL PHOSPHONATE DERIVATTIVES | ILEX PRODUCTS, INC. (US) | 2003-08-21 | — | — | WO | disclosed |
| US-20030040483-A1 | Compounds with growth hormone releasing properties | HELSINN THERAPEUTICS (U.S.), INC. | 2003-02-27 | — | — | US | disclosed |
| US-6127391-A | A PEPTIDE MIMETIC COMPOUND FOR STIMULATING THE RELEASE OF GROWTH HORMONE FROM THE PITUITARY | NOVO NORDISK A/S (DK) | 2000-10-03 | — | — | US | disclosed |
| EP-0563107-B1 | NOVEL METHYLENEBISPHOSPHONIC ACID DERIVATIVES | LEIRAS OY (FI) | 2000-05-03 | — | — | EP | disclosed |
| US-5977178-A | Compounds with growth hormone releasing properties | NOVO NORDISK A/S (DK) | 1999-11-02 | — | — | US | disclosed |
| EP-0869974-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 1998-10-14 | — | — | EP | disclosed |
| US-5393748-A | Treating bone disorders, Paget* s disease, calcium metabolism disorders | LEIRAS OY (FI) | 1995-02-28 | — | — | US | disclosed |
| EP-0563107-A1 | NOVEL METHYLENEBISPHOSPHONIC ACID DERIVATIVES | LEIRAS OY (FI) | 1993-10-06 | — | — | EP | disclosed |
| WO-1992011269-A1 | NOVEL METHYLENEBISPHOSPHONIC ACID DERIVATIVES | LEIRAS OY (FI) | 1992-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124581-A1 | Alpha-substituted heteroarylalkyl phosphonate derivatives | APOB, APOL1, LDLR | FDPS 764/4885HMGCR 24/4885PKM 3013/4885 |
| US-20030040483-A1 | Compounds with growth hormone releasing properties | GHRHR, GHSR, GRPR | FDPS 2950/4885HMGCR 2432/4885PKM 2649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.